Precision medicine, which provides personalized treatments based on individual genomic profiles, has made remarkable progress especially in the oncology area, since when 2 types of comprehensive genomic profiling(CGP)tests, FoundationOne CDx and OncoGuide NCC Oncopanel have been reimbursed by national insurance system in June 2019. However, the application of CGP as a companion diagnostics(CDx)in addition to the single and the multi-CDx tests is now complicated. In this session, problems of the personalized treatment system based on the results of the cancer genomic test will be discussed.
|Number of pages||3|
|Journal||Gan to kagaku ryoho. Cancer & chemotherapy|
|Publication status||Published - 2022 Sep 1|
ASJC Scopus subject areas